Riskpilot← Back to searchSign inGet full accessRoche Pharmaceuticals A/S
A/SActiveCVR 25230515Flaskehalsen 17, 4.Wholesale of pharmaceutical and medical goods · NACE 4646Est. 197093 employees
Revenue 2024
DKK 827M
+9% vs 2023
EBITDA margin
3.5%
+19% vs 2023
Equity ratio
46.1%
Financial strength
Net profit 2024
DKK 24,3M
-34% vs 2023
| Revenue | DKK 827M | +9% |
| EBITDA | DKK 28,9M | +19% |
| Net profit | DKK 24,3M | -34% |
| Total assets | DKK 355,3M | -1% |
| Equity | DKK 163,9M | +17% |
| Employees | 93 | — |
Legal name
Roche Pharmaceuticals A/S
CVR number
25230515
Legal form
Aktieselskab
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
21. januar 1970
Share capital
DKK 4.000.000
Employees
93 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af to bestyrelsesmedlemmer i forening eller af et bestyrelsesmedlem i forening med en direktør
Company purpose
Selskabets formål er A) fabrikation, køb, salg og ind- og udførsel af og agenturvirksomhed for kemiske, farmaceutiske, medicinske bioelektroniske, diagnostiske instrumenter og hjælpemidler. B) videnskablig forskning, udvikling, bearbejdning og afprøvelse af de under A) nævnte produkter C) optagelse af enhver form for virksomhed, som i videste forstand direkte eller indirekte kan tjene til fremme af den ovennævnte formål, herunder, efter forudgående tilladelse fra Handelministeriet, deltagelse i eller køb af aktier i virksomheder, som har beslægtet formål, eller som kan fremme de ovennævnte formål
Address
Flaskehalsen 17, 4.
Phone
+4536399999
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 689.754 | 839.936 | 893.694 | 869.907 | 897.912 | 808.154 | 718.237 | 701.850 | 732.832 | 785.584 | 761.417 | 826.964 |
| Staff expenses | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -24.353 | -0 | -0 | -0 |
| EBITDA | 27.081 | 37.624 | 40.715 | 35.439 | 44.427 | 39.720 | 29.564 | 10.981 | 22.342 | 35.535 | 24.308 | 28.852 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBIT | 27.081 | 37.624 | 40.715 | 35.439 | 44.427 | 39.720 | 29.564 | 10.981 | 22.342 | 35.535 | 24.308 | 28.852 |
| Net financials | -569 | -187 | -145 | -163 | -21 | -17 | -17 | -36 | -34 | 245 | 970 | -3.796 |
| Profit before tax | 26.512 | 37.437 | 40.570 | 35.277 | 44.406 | 39.703 | 29.547 | 16.838 | 22.308 | 35.780 | 43.846 | 31.565 |
| Tax | 12.007 | 10.783 | 11.391 | 9.801 | 11.284 | 9.527 | 7.791 | 4.538 | 6.055 | 16.220 | 7.310 | 7.288 |
| Net profit | 14.505 | 26.654 | 29.179 | 25.476 | 33.122 | 30.177 | 21.755 | 12.300 | 16.253 | 19.560 | 36.536 | 24.277 |
| Item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 302.800 | 333.052 | 315.590 | 311.642 | 361.297 | 323.573 | 351.751 | 378.443 | 354.474 | 389.676 | 357.642 | 355.290 |
| Equity | 88.573 | 100.227 | 129.405 | 124.881 | 158.002 | 138.179 | 159.934 | 127.234 | 143.487 | 163.047 | 139.583 | 163.860 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 210.406 | 223.211 | 180.440 | 183.031 | 200.590 | 182.553 | 190.697 | 237.076 | 208.001 | 217.807 | 216.480 | 186.154 |
| Total debt | 210.406 | 232.825 | 186.184 | 183.031 | 200.590 | 182.553 | 190.697 | 237.076 | 208.701 | 217.807 | 216.480 | 186.154 |
EBITDA margin
3.5%
This company
15.8%
Market median
-78% vs market
20132024
Equity ratio
46.1%
This company
38.2%
Market median
+21% vs market
20132024
Return on equity
14.8%
This company
18.4%
Market median
+20% vs market
20132024
Net profit margin
2.9%
This company
8.1%
Market median
-64% vs market
20132024
Asset turnover
2.33×
This company
1.12×
Market median
+108% vs market
20132024
Debt / equity
1.17×
This company
0.62×
Market median
-89% vs market
20132024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via CVR / Virk · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via CVR / Virk · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via CVR / Virk · Period 2013-01-01 – 2013-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
RJ Management | Management | 2014 | — | — |
LJ Management | Management | 2014 | — | — |
CH Chief Executive Officer | Chief Executive Officer | 2025 | — | — |
RF Management | Management | 1996 | — | — |
CH Chief Executive Officer | Chief Executive Officer | 2025 | — | — |
LV Management | Management | 2017 | — | — |
JT Management | Management | 1970 | — | — |
DG Chief Executive Officer | Chief Executive Officer | 2021 | — | — |
WA Management | Management | 1970 | — | — |
RS Management | Management | 2006 | — | — |
JF Management | Management | 2012 | — | — |
EP Management | Management | 1970 | — | — |
RJ Management | Management | 2017 | — | — |
DP Management | Management | 2003 | — | — |
MF Chief Executive Officer | Chief Executive Officer | 2025 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2013 | — | — | |
| Board of Directors | 2019 | — | — | |
| Deputy Chairman | 2001 | — | — | |
| Board of Directors | 1970 | — | — | |
| Board of Directors | 2007 | — | — | |
| Board of Directors | 1970 | — | — | |
| Board of Directors | 1970 | — | — | |
| Deputy Chairman | 1999 | — | — | |
| Board of Directors | 1970 | — | — | |
| Chairman | 2022 | — | — | |
| Chairman | 2019 | — | — | |
| Chairman | 2001 | — | — | |
| Board of Directors | 1970 | — | — | |
| Board of Directors | 1970 | — | — | |
| Board of Directors | 2003 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 100.0% | 100.0% | 2015 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Roche Pharmaceuticals A/S also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Ronald Jeyung Park | Management | 0 companies |
| Luc Jozef Leon Dirckx | Management | 0 companies |
| Carole Hassoun | Chief Executive Officer | 0 companies |
| Rudolf Fischer | Management | 0 companies |
| Carole Hassoun | Chief Executive Officer | 0 companies |
| Linda Valentin Vestergaard | Management | 0 companies |
| Jean-Willy Tanner | Management | 0 companies |
| Darine Ghanem | Chief Executive Officer | 0 companies |
| Walter Alwin Werner | Management | 0 companies |
| Robin Stephen Turner | Management | 0 companies |
| Janet Friedman Makepeace | Management | 0 companies |
| Ernst Peter Krebs | Management | 0 companies |
| Richard John Wright | Management | 0 companies |
| Daniel Patrick O'Day | Management | 0 companies |
| Maria Falkenberg Petersen | Chief Executive Officer | 0 companies |
| Jennifer Elizabeth Cook | Board of Directors | 0 companies |
| Ehab Abdelmoneim Youssef Hassan | Board of Directors | 0 companies |
| Claude Georges Charles Schreiner | Deputy Chairman | 0 companies |
| Ole Nørregaard | Board of Directors | 0 companies |
| Peter Hug | Board of Directors | 0 companies |
| Ole Brøns | Board of Directors | 0 companies |
| Andreas Friedrich Leuenberger | Board of Directors | 0 companies |
| William Murray Burns | Deputy Chairman | 0 companies |
| Markus Christoph Altwegg | Board of Directors | 0 companies |
| Isabel Marianne Joerin | Chairman | 0 companies |
| Beat Christoph Krähenmann | Chairman | 0 companies |
| Michael Egede Budtz | Chairman | 0 companies |
| Armin Maximilian Kessler | Board of Directors | 0 companies |
| Otto August Meile | Board of Directors | 0 companies |
| Daniel Patrick O'Day | Board of Directors | 0 companies |